Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16043880 | 1.00 | LMNA (0.44) | LMNAHTTTP53CYP2C9TSHR | |
| SCHEMBL16044116 | 1.00 | LMNA (0.44) | LMNAHTTTP53CYP2C9TSHR | |
| SCHEMBL2609312 | 0.83 | LMNA (0.44) | LMNAHTTTP53CYP2C9TSHR | |
| SCHEMBL18244479 | 0.81 | LMNA (0.42) | LMNAHTTCYP2C9TSHRAPEX1 | |
| SCHEMBL29441178 | 0.80 | KMT2A (0.35) | LMNAHTTTP53SMN1; SMN2MAPK1 | |
| SCHEMBL17823946 | 0.80 | KMT2A (0.35) | LMNAHTTTP53SMN1; SMN2MAPK1 | |
| SCHEMBL13119982 | 0.80 | S1PR1 (0.47) | LMNAHTTTP53PLAUS1PR1 | |
| SCHEMBL17823722 | 0.80 | S1PR3 (0.42) | S1PR1S1PR3 | |
| SCHEMBL21725703 | 0.80 | S1PR3 (0.42) | S1PR1S1PR3 | |
| SCHEMBL29441073 | 0.80 | S1PR3 (0.42) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228132-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-11-07 | — | — | WO | disclosed |
| US-7074742-B2 | Pyridinyl amides and imides for use as fungicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050020643-A1 | Pyridinyl amides and compositions thereof for use as fungicides | E.I. DU PONT DE NEMOURS AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| EP-1485355-A2 | PYRIDINYL AMIDES AND COMPOSITIONS THEREOF FOR USE AS FUNGICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040044040-A1 | Pyridinyl amides and imides for use as fungicides | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003080576-A2 | PYRIDINYL AMIDES AND COMPOSITIONS THEREOF FOR USE AS FUNGICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044040-A1 | Pyridinyl amides and imides for use as fungicides | CBR1, CBR3, AOC3 | LMNA 1500/4885HTT 4580/4885TP53 4794/4885 |
| US-20050020643-A1 | Pyridinyl amides and compositions thereof for use as fungicides | ME3, CYC1, ME2 | LMNA 2451/4885HTT 4182/4885TP53 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.